Trial Profile
A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Linrodostat (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 27 Feb 2023 Planned End Date changed from 1 Jul 2024 to 10 Nov 2026.
- 27 Feb 2023 Planned primary completion date changed from 31 Jan 2023 to 22 Apr 2024.
- 27 Feb 2023 Status changed from recruiting to active, no longer recruiting.